Oramed Pharmaceuticals Stock Investor Sentiment

ORMP Stock  USD 2.37  0.02  0.85%   
Slightly above 52% of Oramed Pharmaceuticals' retail investors are presently thinking to get in. The analysis of overall sentiment of trading Oramed Pharmaceuticals stock suggests that some investors are interested at this time. Oramed Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Oramed Pharmaceuticals. Many technical investors use Oramed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Oramed Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Oramed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at www.macroaxis.com         
Acquisition by Gabay Avraham of 140040 shares of Oramed Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Oramed Announces Closing of 50 Million Registered Direct Offering of Common Stock Priced At-the-Mark...
Google News at Macroaxis
over three months ago at news.google.com         
Insider Trading
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Scilex Holding Company Announces 5-Year Term of 100 Million Financing with Royalty-Based Payments an...
Yahoo News
over three months ago at news.google.com         
Oramed Pharmaceuticals Stock Passes Below Two Hundred Day Moving Average of 2.54 - Defense World
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Reznick Yehuda of 760 shares of Oramed Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Oramed Pharmaceuticals Shares Cross Below 200 Day Moving Average of 2.53 - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
ORMP Moving Oral Delivery Platform Forward, Potential to Generate Royalties
Yahoo News
over six months ago at news.google.com         
Acquisition by Kidron Nadav of 150000 shares of Oramed Pharmaceuticals subject to Rule 16b-3
Google News at Macroaxis
over six months ago at news.google.com         
Oramed Pharmaceuticals Neutral Rating Reiterated at HC Wainwright - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
HC Wainwright Reiterates Neutral Rating for Oramed Pharmaceuticals - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Oramed Pharmaceuticals Granted Japanese Patent for GLP-1 Analog Capsule - Marketscreener.com
Google News at Macroaxis
over six months ago at investing.com         
Compugen names David Silberman as new CFO
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Compugen Appoints David Silberman as Chief Financial Officer
Yahoo News
over six months ago at finance.yahoo.com         
Oramed Pharmaceuticals First Quarter 2024 Earnings EPS US0.038
Yahoo News
Far too much social signal, news, headlines, and media speculation about Oramed Pharmaceuticals that are available to investors today. That information is available publicly through Oramed media outlets and privately through word of mouth or via Oramed internal channels. However, regardless of the origin, that massive amount of Oramed data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oramed Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oramed Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oramed Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oramed Pharmaceuticals alpha.

Oramed Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
ORMP - Oramed Pharmaceuticals Inc. Latest Stock News Market Updates - StockTitan
10/07/2024
2
Scilex Holdings CEO Jaisim Shah purchases 29,751 in common stock
10/17/2024
3
Scilex director Chun Jay acquires 4,750 in common stock
10/18/2024
4
Scilex executive chairperson Ji Henry buys 8,351 in stock
10/31/2024
5
Acquisition by Joshua Hexter of 30000 shares of Oramed Pharmaceuticals subject to Rule 16b-3
11/07/2024
6
Oramed Pharmaceuticals Share Price Passes Below 200-Day Moving Average - Should You Sell - MarketBeat
11/20/2024

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.